BR112021017203A2 - Leucina, acetil leucina e análogos relacionados para o tratamento de doenças - Google Patents
Leucina, acetil leucina e análogos relacionados para o tratamento de doençasInfo
- Publication number
- BR112021017203A2 BR112021017203A2 BR112021017203A BR112021017203A BR112021017203A2 BR 112021017203 A2 BR112021017203 A2 BR 112021017203A2 BR 112021017203 A BR112021017203 A BR 112021017203A BR 112021017203 A BR112021017203 A BR 112021017203A BR 112021017203 A2 BR112021017203 A2 BR 112021017203A2
- Authority
- BR
- Brazil
- Prior art keywords
- leucine
- pharmaceutically acceptable
- acceptable salt
- acetyl
- diseases
- Prior art date
Links
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 title abstract 3
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title abstract 3
- 229960000669 acetylleucine Drugs 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 7
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 abstract 1
- WXNXCEHXYPACJF-SSDOTTSWSA-N N-acetyl-D-leucine Chemical compound CC(C)C[C@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-SSDOTTSWSA-N 0.000 abstract 1
- WXNXCEHXYPACJF-UHFFFAOYSA-N N-acetyl-leucine Chemical compound CC(C)CC(C(O)=O)NC(C)=O WXNXCEHXYPACJF-UHFFFAOYSA-N 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- QIGLJVBIRIXQRN-ZETCQYMHSA-N ethyl (2s)-2-amino-4-methylpentanoate Chemical compound CCOC(=O)[C@@H](N)CC(C)C QIGLJVBIRIXQRN-ZETCQYMHSA-N 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
leucina, acetil leucina e análogos relacionados para o tratamento de doenças. a presente divulgação fornece métodos de tratamento de doenças, distúrbios, condições ou síndromes, por exemplo, lesão cerebral traumática, em um paciente em necessidade, através da administração de uma quantidade terapeuticamente eficaz de dl-leucina, ou um sal farmaceuticamente aceitável deste, l-leucina, ou um sal farmaceuticamente aceitável deste, d-leucina, ou um sal farmaceuticamente aceitável deste, éster etílico de l-leucina, ou um sal farmaceuticamente aceitável deste, acetil-dl-leucina, ou um sal farmaceuticamente aceitável deste, acetil-d-leucina, ou um sal farmaceuticamente aceitável deste, ou acetil-l-leucina, ou um sal farmaceuticamente aceitável deste.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812987P | 2019-03-02 | 2019-03-02 | |
| US201962842296P | 2019-05-02 | 2019-05-02 | |
| US201962888894P | 2019-08-19 | 2019-08-19 | |
| US201962895144P | 2019-09-03 | 2019-09-03 | |
| PCT/IB2020/051767 WO2020178721A1 (en) | 2019-03-02 | 2020-03-02 | Leucine, acetyl leucine, and related analogs for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017203A2 true BR112021017203A2 (pt) | 2021-12-14 |
Family
ID=69845470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017203A BR112021017203A2 (pt) | 2019-03-02 | 2020-03-02 | Leucina, acetil leucina e análogos relacionados para o tratamento de doenças |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220142959A1 (pt) |
| EP (1) | EP3934637B1 (pt) |
| JP (1) | JP7555346B2 (pt) |
| KR (1) | KR20210135272A (pt) |
| CN (1) | CN114040757B (pt) |
| AU (1) | AU2020231189A1 (pt) |
| BR (1) | BR112021017203A2 (pt) |
| CA (1) | CA3131948A1 (pt) |
| DK (1) | DK3934637T3 (pt) |
| FI (1) | FI3934637T3 (pt) |
| IL (1) | IL285870A (pt) |
| LT (1) | LT3934637T (pt) |
| MA (1) | MA55199A (pt) |
| MX (1) | MX2021010568A (pt) |
| PT (1) | PT3934637T (pt) |
| RS (1) | RS65849B1 (pt) |
| SG (1) | SG11202109512SA (pt) |
| WO (1) | WO2020178721A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| US20220024858A1 (en) * | 2018-12-06 | 2022-01-27 | Intrabio Ltd. | Deuterated analogs of acetyl-leucine |
| WO2022125304A1 (en) * | 2020-12-10 | 2022-06-16 | Texas Tech University System | Bcaa-lowering compounds for prevention and/or treatment of alzheimer's disease and related disorders |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| PE20230169A1 (es) | 2010-06-25 | 2023-02-01 | Shire Human Genetic Therapies | Suministro al sistema nervioso central de agentes terapeuticos |
| US20140080885A1 (en) * | 2012-09-13 | 2014-03-20 | University Of South Florida (A Florida Non-Profit Corporation) | Methods of treating traumatic brain injury |
| CN109069463B (zh) * | 2016-04-19 | 2024-07-23 | 内在生物技术有限公司 | 用于改善运动能力和认知功能的乙酰亮氨酸或其药学上可接受的盐 |
| TN2016000259A1 (en) * | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
| IL264610B1 (en) | 2016-08-11 | 2024-08-01 | Intrabio Ltd | Pharmaceutical preparations and uses targeting lysosomal storage disorders |
| JP6957602B2 (ja) | 2016-08-11 | 2021-11-02 | イントラバイオ リミティド | 神経変性疾患のための治療薬 |
| EP3684350A1 (en) | 2017-08-14 | 2020-07-29 | Axcella Health Inc. | Amino acids compositions for the treatment of neuronal injury |
-
2020
- 2020-03-02 PT PT207120296T patent/PT3934637T/pt unknown
- 2020-03-02 DK DK20712029.6T patent/DK3934637T3/da active
- 2020-03-02 MA MA055199A patent/MA55199A/fr unknown
- 2020-03-02 FI FIEP20712029.6T patent/FI3934637T3/fi active
- 2020-03-02 CA CA3131948A patent/CA3131948A1/en active Pending
- 2020-03-02 LT LTEPPCT/IB2020/051767T patent/LT3934637T/lt unknown
- 2020-03-02 CN CN202080029158.5A patent/CN114040757B/zh active Active
- 2020-03-02 SG SG11202109512SA patent/SG11202109512SA/en unknown
- 2020-03-02 WO PCT/IB2020/051767 patent/WO2020178721A1/en active Application Filing
- 2020-03-02 KR KR1020217031422A patent/KR20210135272A/ko unknown
- 2020-03-02 JP JP2021551939A patent/JP7555346B2/ja active Active
- 2020-03-02 RS RS20240913A patent/RS65849B1/sr unknown
- 2020-03-02 BR BR112021017203A patent/BR112021017203A2/pt unknown
- 2020-03-02 MX MX2021010568A patent/MX2021010568A/es unknown
- 2020-03-02 EP EP20712029.6A patent/EP3934637B1/en active Active
- 2020-03-02 US US17/435,784 patent/US20220142959A1/en active Pending
- 2020-03-02 AU AU2020231189A patent/AU2020231189A1/en active Pending
-
2021
- 2021-08-25 IL IL285870A patent/IL285870A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3934637T3 (da) | 2024-09-02 |
| EP3934637A1 (en) | 2022-01-12 |
| RS65849B1 (sr) | 2024-09-30 |
| JP2022522819A (ja) | 2022-04-20 |
| KR20210135272A (ko) | 2021-11-12 |
| EP3934637B1 (en) | 2024-07-31 |
| CN114040757B (zh) | 2024-09-20 |
| AU2020231189A1 (en) | 2021-09-30 |
| US20220142959A1 (en) | 2022-05-12 |
| SG11202109512SA (en) | 2021-09-29 |
| CA3131948A1 (en) | 2020-09-10 |
| PT3934637T (pt) | 2024-08-30 |
| IL285870A (en) | 2021-10-31 |
| CN114040757A (zh) | 2022-02-11 |
| FI3934637T3 (fi) | 2024-09-02 |
| MX2021010568A (es) | 2021-11-12 |
| WO2020178721A1 (en) | 2020-09-10 |
| JP7555346B2 (ja) | 2024-09-24 |
| MA55199A (fr) | 2022-01-12 |
| LT3934637T (lt) | 2024-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021017203A2 (pt) | Leucina, acetil leucina e análogos relacionados para o tratamento de doenças | |
| MX2019004616A (es) | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| MX2019012884A (es) | Terapia de combinacion. | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| BR112021026334A2 (pt) | Macrófagos ativados por hdac6, composições, e usos dos mesmos | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| BR112022000231A2 (pt) | Novos métodos | |
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| PH12021551541A1 (en) | Compositions and methods for treating neurodegenerative disorders | |
| BR112019002461A2 (pt) | regime de dosagem para tratamento de tumores sólidos | |
| BR112018014920A2 (pt) | métodos de autofagia por modulação, de tratamento ou redução da probabilidade do início de uma condição mediada por autofagia, de tratamento, inibição, redução, diminuição, ou prevenção de um distúrbio relacionado à idade, de modulação da expressão ou atividade de pelo menos um fator de transcrição, de tratamento, prevenção, diminuição, inibição ou redução de uma condição patológica atribuível a um estado de excesso de nutriente, de promoção de longevidade por autofagia por modulação, de aumento da duração de tempo que um mamífero pode levar um estilo de vida ativo sem sofrer de condições associadas com envelhecimento e de prolongamento do período de saúde de um mamífero. | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| TW201625286A (zh) | 靈芝免疫調節蛋白於促進神經突生長之新用途 | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| RU2007112950A (ru) | Новые производные 3,5-секо-4-норхолестана и их применение | |
| BR112019023817A8 (pt) | Composições tópicas e métodos para o tratamento de doenças da pele | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same |